Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

The best metric is not weight, but a particularly toxic kind of fat.

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...